What it is: A synthetic analog of IGF-1 with structural modifications that extend its half-life to approximately 20-30 hours and dramatically increase its biological potency.
Research suggests: Strongly promotes muscle protein synthesis and cellular repair; most direct human evidence is extrapolated from clinical trials of native recombinant IGF-1.
Best for: Anabolic and body composition researchers
Key thing to know: Hypoglycemia risk is well-documented and significant; blood glucose monitoring is a standard consideration in any research protocol involving this compound.
What is IGF-1 LR3?
IGF-1 LR3 (Insulin-like Growth Factor 1 Long R3) is a synthetic analog of IGF-1 with two modifications: an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These reduce its binding to IGF binding proteins (IGFBPs) that normally limit its activity. The result is greater potency and a half-life roughly 120 times longer than endogenous IGF-1.
Endogenous IGF-1 is produced mainly in the liver in response to growth hormone (GH) signaling and is central to the GH/IGF-1 axis, one of the body's main anabolic systems, promoting cellular growth, protein synthesis, glucose uptake, and muscle repair. IGF-1 LR3 was developed as a research tool to study sustained IGF-1 receptor activation without native IGF-1's short half-life.
Research interest is concentrated in areas of skeletal muscle hypertrophy, recovery from injury, fat metabolism, and the cellular biology of aging. It is not approved for human use and carries a distinct risk profile due to its potency and mitogenic properties.
How it works.
In research, the proposed mechanism has several parts.
IGF-1 receptor: IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor expressed on nearly all cell types. This binding triggers autophosphorylation of the receptor and downstream activation of two primary signaling cascades: the PI3K/Akt/mTOR pathway (which drives protein synthesis, cell growth, and survival) and the MAPK/ERK pathway (which promotes cell proliferation and differentiation).
mTOR pathway: The mTOR pathway is particularly relevant to skeletal muscle: mTORC1 activation increases ribosomal biogenesis and protein translation, raising muscle protein synthesis rates. Cell-culture and preclinical studies show IGF-1 LR3 can initiate satellite cell activation — the proliferation of muscle stem cells that repair and add to muscle fibers after mechanical stress or injury.
Reduced IGFBP binding: Because IGF-1 LR3 binds IGFBPs less, a higher fraction stays free and biologically active than native IGF-1. Its extended half-life (about 20–30 hours versus 12–15 minutes for endogenous IGF-1) means prolonged receptor activation — useful for studying sustained anabolic signaling, but also a concern regarding unchecked mitogenic activity in tissues with pre-existing abnormalities.
What the research shows.
The research evidence breaks down as follows.
A split evidence base: The evidence base is split between robust in-vitro and animal research and limited direct human data. In cell-culture and rodent studies, IGF-1 LR3 consistently shows enhanced muscle protein synthesis, faster satellite cell proliferation, improved glycogen storage, and reduced adipogenesis. These mechanistic effects are well-characterized and replicated across independent groups.
Human data: Human data is more limited. Much of it is extrapolated from trials on native recombinant IGF-1 (mecasermin). Those show IGF-1 receptor activation produces measurable anabolic effects and influences insulin sensitivity — mechanistic plausibility for LR3 — but the LR3 analog's specific pharmacokinetics and safety in humans have not been directly studied.
Research-chemical context: The research chemical context adds complexity: IGF-1 LR3 is used in research settings but has not undergone the clinical trial pipeline required to characterize its human safety profile at various doses and durations. The absence of clinical data is not evidence of ineffectiveness, but it does mean the risk profile in humans is not well-established.
Biomarkers to review first.
Research protocols for IGF-1 LR3 typically reference the following biomarkers as critical baseline context. Given IGF-1 LR3's effects on insulin signaling and cellular growth, these markers are especially important to understand before any protocol consideration.
What it's commonly researched with.
In research literature, IGF-1 LR3 is frequently examined in combination with growth hormone secretagogues and recovery-focused peptides. The combinations below represent what researchers have studied - not recommendations for use.